🇺🇸 FDA
Pipeline program

fluticasone furoate/vilanterol

113684

Phase 3 small_molecule completed

Quick answer

fluticasone furoate/vilanterol for Pulmonary Disease, Chronic Obstructive is a Phase 3 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).

Program details

Company
GlaxoSmithKline
Indication
Pulmonary Disease, Chronic Obstructive
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials